https://orcid.org/0000-0002-8333-414X
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Objective
l-Carnitine has been suggested as a potential nutrient that alleviates the oxidative and inflammatory damages of coronary artery disease (CAD), but the results of the previous studies of the importance of this supplementation remains unclear. This study attempts to evaluate the effects of l-carnitine (LC) supplementation on oxidative stress and inflammatory biomarkers in patients with CAD.
Methods
A double-blind, randomised, placebo-trial was conducted on 75 CAD subjects. Patients were randomly assigned to receive LC (1000 mg/day) or placebo capsules over 3 months. Sera high-sensitivity C-reactive protein (hs-CRP), myeloperoxidase (MPO), nitrotyrosine (NT) and total antioxidant capacity (TAC) were assayed.
Results
A significant increase in serum TAC and a significant decrease in MPO, NT, and hs-CRP levels were detected following 12 weeks of LC supplementation, compared to the placebo.
Conclusions
These results suggest that LC supplementation may exert beneficial effect on cardiovascular health through attenuate oxidative and inflammatory markers in CAD patients.
Ethical approval
The trial was given ethical approval by the Ethics Committee of the Deputy of Research and Technology of Kermanshah University of Medical Sciences (ethics approval number: KUMS.REC.1395.80) and registered with the Iranian Clinical Trials Registry (registration number IRCT2016060528260N1).
Acknowledgements
The authors thank all participants for their contributions and also greatly appreciate the support they received from the Deputy of Research and Technology of Kermanshah University of Medical Sciences.
Disclosure statement
The authors declare that they have no conflict of interest.